Xbiotech derives its vaccines from humans because it creates fewer adverse reactions and superior performance that way said the company’s CEO John Simard. 'In a guinea pig, or a mouse or a rat or a chicken, or a test tube, which is where most antibodies come from now, that engineering can’t be vetted in the context of the human body,' said Simard. 'The only place to get an antibody that is safe and that doesn’t hurt you is go into a person and get one of those that were tested and vetted in the human immune system.' Austin Texas-based XBiotech went public at $19 a share in mid-April and quickly jumped above $31. The shares have drifted lower since then and changed hands around $17 at last check. The company announced this week the publication of Type 2 diabetes clinical results which showed that the company’s antibody therapy not only improved measures of glucose control, but also reduced blood pressure in the patients.